Is IRadimed Corp. overvalued or undervalued?

As of 17 October 2025, the valuation grade for IRadimed Corp. has moved from expensive to attractive, indicating a shift in perception towards the stock's value. The company appears undervalued based on its current metrics, with a P/E ratio of 39, a Price to Book Value of 8.54, and an EV to EBITDA ratio of 30.68, which suggest that the stock is trading at a reasonable valuation compared to its earnings and book value.
In comparison to its peers, IRadimed Corp. has a more favorable valuation with a PEG ratio of 3.97, while Artivion, Inc. shows a negative P/E of -268.22 and BioLife Solutions, Inc. also has a negative P/E of -62.83, highlighting IRadimed's relative strength in the market. Furthermore, the company has outperformed the S&P 500 significantly over multiple periods, with a year-to-date return of 33.51% compared to the S&P 500's 13.30%, reinforcing the attractiveness of the stock.